SESN1 is a FOXO3 effector that counteracts human skeletal muscle ageing

Cell Prolif. 2023 May;56(5):e13455. doi: 10.1111/cpr.13455. Epub 2023 May 17.

Abstract

Sarcopenia, a skeletal muscle disorder in which loss of muscle mass and function progresses with age, is associated with increased overall frailty, risk of falling and mortality in the elders. Here, we reveal that SESN1 safeguards skeletal muscle from ageing downstream of the longevity gene FOXO3, which we recently reported is a geroprotector in primate skeletal muscle. Knockdown of SESN1 mimicked the human myotube ageing phenotypes observed in the FOXO3-deficient human myotubes, whereas genetic activation of SESN1 alleviated human myotube senescence. Of note, SESN1 was identified as a protective secretory factor against muscle atrophy. Administration of recombinant SESN1 protein attenuated senescence of human myotubes in vitro and facilitated muscle regeneration in vivo. Altogether, we unveil a key role of SESN1 downstream of FOXO3 in protecting skeletal muscle from ageing, providing diagnostic biomarkers and intervention strategies for counteracting skeletal muscle ageing and related diseases.

MeSH terms

  • Aged
  • Aging
  • Animals
  • Forkhead Box Protein O3 / genetics
  • Forkhead Box Protein O3 / metabolism
  • Humans
  • Muscle Fibers, Skeletal / metabolism
  • Muscle, Skeletal* / metabolism
  • Muscular Atrophy / metabolism
  • Sarcopenia* / pathology
  • Sestrins* / metabolism
  • Transcription Factors / metabolism

Substances

  • Forkhead Box Protein O3
  • FOXO3 protein, human
  • SESN1 protein, human
  • Sestrins
  • Transcription Factors

Grants and funding